PURPOSE: To summarize the global predicting role of systemic inflammatory response for survival in renal cell carcinoma. METHODS: Eligible studies were identified and assessed for quality through multiple search strategies. Data were collected from studies comparing overall, cancer-specific or relapse-free survival in patients with elevated C-reactive protein (CRP), platelet count (PC) and erythrocyte sedimentation rate (ESR) levels with those with lower levels. Studies were pooled, and combined hazard ratios (HRs) of CRP, PC and ESR for survival were calculated, respectively. RESULTS: A total of 47 studies were included for meta-analysis (18 for CRP, 15 for PC and 14 for ESR). For overall survival, the pooled HR of CRP (3.23, 95% CI: 1.77, 5.89) was higher than that of PC (1.96, 95% CI: 1.40, 2.75) and that of ESR (1.86, 95% CI: 1.34, 2.59). These indicators were strong predictors for cancer-specific survival with individual HRs being 3.46 (95% CI, 2.80, 4.27) of CRP, 3.22 (95% CI, 2.25, 4.62) of PC, and 3.85 (95% CI, 3.31, 4.48) of ESR, respectively. All three inflammatory indictors also predicted relapse-free survival (HRs > 2.0). CONCLUSION: The systemic inflammatory response predicted poor survival in patients with renal cell carcinoma.
PURPOSE: To summarize the global predicting role of systemic inflammatory response for survival in renal cell carcinoma. METHODS: Eligible studies were identified and assessed for quality through multiple search strategies. Data were collected from studies comparing overall, cancer-specific or relapse-free survival in patients with elevated C-reactive protein (CRP), platelet count (PC) and erythrocyte sedimentation rate (ESR) levels with those with lower levels. Studies were pooled, and combined hazard ratios (HRs) of CRP, PC and ESR for survival were calculated, respectively. RESULTS: A total of 47 studies were included for meta-analysis (18 for CRP, 15 for PC and 14 for ESR). For overall survival, the pooled HR of CRP (3.23, 95% CI: 1.77, 5.89) was higher than that of PC (1.96, 95% CI: 1.40, 2.75) and that of ESR (1.86, 95% CI: 1.34, 2.59). These indicators were strong predictors for cancer-specific survival with individual HRs being 3.46 (95% CI, 2.80, 4.27) of CRP, 3.22 (95% CI, 2.25, 4.62) of PC, and 3.85 (95% CI, 3.31, 4.48) of ESR, respectively. All three inflammatory indictors also predicted relapse-free survival (HRs > 2.0). CONCLUSION: The systemic inflammatory response predicted poor survival in patients with renal cell carcinoma.
Authors: Jacopo Peccatori; Lisbeth Barkholt; Tanner Demirer; Maria Pia Sormani; Paolo Bruzzi; Fabio Ciceri; Alberto Zambelli; Gian Antonio Da Prada; Paolo Pedrazzoli; Salvatore Siena; Gero Massenkeil; Rodrigo Martino; Stig Lenhoff; Paolo Corradini; Giovanni Rosti; Olle Ringden; Marco Bregni; Dietger Niederwieser Journal: Cancer Date: 2005-11-15 Impact factor: 6.860
Authors: Pierre I Karakiewicz; Georg C Hutterer; Quoc-Dien Trinh; Claudio Jeldres; Paul Perrotte; Andrea Gallina; Jacques Tostain; Jean-Jacques Patard Journal: Cancer Date: 2007-09-15 Impact factor: 6.860
Authors: Kang Su Cho; Young Deuk Choi; Se Joong Kim; Chun Il Kim; Byung Ha Chung; Do Hwan Seong; Dong Hyeon Lee; Jin Seon Cho; In Rae Cho; Sung Joon Hong Journal: Yonsei Med J Date: 2008-06-30 Impact factor: 2.759
Authors: Todd M Morgan; Dominic Tang; Kelly L Stratton; Daniel A Barocas; Christopher B Anderson; Justin R Gregg; Sam S Chang; Michael S Cookson; S Duke Herrell; Joseph A Smith; Peter E Clark Journal: Eur Urol Date: 2011-01-28 Impact factor: 20.096
Authors: Benita Wolf; Adrian Schwarzer; Anik L Côté; Thomas H Hampton; Thomas Schwaab; Eduardo Huarte; Craig R Tomlinson; Jiang Gui; Jan L Fisher; Camilo E Fadul; Joshua W Hamilton; Marc S Ernstoff Journal: PLoS One Date: 2012-12-03 Impact factor: 3.240
Authors: Brian W Cross; Timothy V Johnson; Austin B Derosa; Kenneth Ogan; John G Pattaras; Peter T Nieh; Omer Kucuk; Wayne B Harris; Viraj A Master Journal: Int J Surg Oncol Date: 2012-07-29